AI tool jointly developed by Hadassah Medical Center – SHL Telemedicine – Hebrew University

Prediction of future life-threatening cardiac events based on SHL ECG devices, including SmartHeart™ technology, enabling performing a remote full 12 Lead ECG by any person Tel Aviv / Zurich, 2 November 2020 – SHL Telemedicine Ltd. (SIX Swiss Exchange: SHLTN), a world leader in the field of portable hospital quality FDA cleared full ECG (12 Lead) for personal use, and the Hebrew University of Jerusalem, through Yissum Research Development Company of the Hebrew University of Jerusalem Ltd., and Hadassah Medical Center, through Hadasit Medical Research and Development Services Ltd. – today announced an agreement to develop an Artificial Intelligence – AI tool for predicting future life-threatening cardiac events based on full 12 Lead ECG monitoring. For more information Click here